It should also be mentioned that despite the similarly low level of expression of TAAR1, the agonist of this receptor, Ulotaront, showed clinical efficacy in patients with schizophrenia, ameliorating both positive and negative symptoms without causing side effects of currently used antipsychotics [67,68,69,70]. Here, TAAR1 is linked to schizophrenia.